Drug intelligence / Profile preview

Imunoinstant Multiplu

Development stage
Unknown
Lead developer
ROMVAC
Modality
Antibody-Based Therapeutics
Administration
Oral
01

Overview

Imunoinstant Multiplu is an oral solution containing polyclonal IgY antibodies (immunoglobulin Y) extracted from the egg yolks of hens immunized against a broad spectrum of human pathogens. Developed by the Romvac Company, it is designed to provide passive immunity by directly neutralizing bacteria, viruses, and fungi in the gastrointestinal tract and oropharyngeal cavity. The product is marketed as a food supplement intended to support the immune system against infections caused by over 18 different pathogens, including *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Escherichia coli*, and *Candida albicans*. By binding to specific surface antigens of these pathogens, the IgY antibodies prevent their adherence to host tissues and neutralize their pathogenic effects, offering a non-antibiotic approach to managing microbial imbalances and infections.

Brand names
Imunoinstant Multiplu
Other names
Imunoinstant Multiplu Oral SolutionIgY Multiplu
02

Targets

Helicobacter pylori surface antigensSlpA (Surface layer protein A)Streptococcus agalactiae surface antigensCandida albicans surface antigensKlebsiella pneumoniae surface antigensEnterococcus faecalis surface antigensSpA (Staphylococcal protein A)AgI/II (Antigen I/II)Salmonella surface antigen

Beyond the preview

Go deeper on Imunoinstant Multiplu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imunoinstant Multiplu.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call